Yuekang pharmaceutical YKYY013 injection obtained clinical trial approval from the US FDA.

On the evening of September 22, YK Pharmaceutical announced that its subsidiary, Beijing YK Science and Technology Pharmaceutical Co., Ltd., has received a letter from the U.S. Food and Drug Administration approving the clinical trial of YKYY013 injection for the treatment of chronic hepatitis B virus infection.